Strain differences in diazepam metabolism at its three metabolic sites in Sprague-Dawley, Brown Norway, Dark Agouti, and Wistar strain rats

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 959-965

  Saito, Konomu ^a   Sakai, Noriaki ^a   Kim, Hyung Sub ^a   Ishizuka, Mayumi ^a   Kazusaka, Akio ^a   Fujita, Shoichi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYDIAZEPAM; CYTOCHROME P450 2D1; CYTOCHROME P450 3A2; DIAZEPAM; DRUG METABOLITE; NORDAZEPAM; TEMAZEPAM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; LIVER MICROSOME; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; STRAIN DIFFERENCE; TOXICITY TESTING;

ALCOHOL OXIDOREDUCTASES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAZEPAM; HYDROXYLATION; IMMUNE SERA; KINETICS; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; NADP; POLYMORPHISM, GENETIC; RATS; RATS, INBRED BN; RATS, INBRED STRAINS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPECIES SPECIFICITY; STEROID 16-ALPHA-HYDROXYLASE; TEMAZEPAM;

AGOUTI; ANIMALIA; RATTUS NORVEGICUS;

EID: 4143125870     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Adedoyin A, Arns PA, Richards WO, Wilkinson GR, and Branch RA (1998) Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 64:8-17.
2. Bert B, Fink H, Sohr R, and Rex A (2001) Different effects of diazepam in Fischer rats and two stocks of Wistar rats in tests of anxiety. Pharmacol Biochem Behav 70:411-420.
3. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, and Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355.
4. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361.
5. Fujila S, Chiba M, Ohta M, Kitani K, and Suzuki T (1990a) Alteration of plasma sex hormone levels associated with old age and its effect on hepatic drug metabolism in rats. J Pharmacol Exp Ther 253:369-374.
6. Fujita S, Kitagawa H, Ishizawa H, Suzuki T, and Kitani K (1985) Age-associated alterations in hepatic glutathione-S-taransferaces. Biochem Pharmacol 34:3891-3894.
7. Fujita S, Tatsuno J, Kitani K, and Suzuki T (1990b) Age-associated alterations in diazepam metabolizing enzyme activities in male and female rats. Drug Metab Dispos 18:812-814.
8. He N, Yan FX, Huang SL, Wang W, Xiao ZS, Liu ZQ, and Zhou HH (2002) CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol 58:15-18.
9. Hiroi T, Chow T, Imaoka S, and Funae Y (2002) Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30:970-976.
10. Inaba T, Tait A, Nakano M, Mahon WA, and Kalow W (1988) Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation. Drug Metab Dispos 16:605-608.
11. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (Lond) 227:680-685.
12. Lennard PR (1990) Image analysis for all. Nature (Lond) 347:103-104.
13. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
14. Marandi T, Dahl ML, Kiivet RA, Rago L, and Sjoqvist F (1996) Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Pharmacol Toxicol 78:303-307.
15. Marandi T, Dahl ML, Rago L, Kiivet R, and Sjoqvist F (1997) Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Eur J Clin Pharmacol 53:257-260.
16. Masubuchi Y, Umeda S, Igarashi S, Fujita S, Narimatsu S, and Suzuki T (1993) Participation of the CYP2D subfamily in lidocaine 3-hydroxylation and formation of a reactive metabolite covalently bound to liver microsomal protein in rats. Biochem Pharmacol 46:1867-1869.
17. Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, and Green R (2002) A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters and their response to diazepam. Psychopharmacology (Berl) 159:188-195.
18. Nakamura A, Yamamoto Y, Sugimoto C, Masuda M, Kazusaka A, and Fujita S (1995) Anti-peptide antibodies to the P4502D subfamily in rat, dog and man. Xenobiotica 25:1103-1009.
19. Neville CF, Ninomiya S, Shimada N, Kamataki T, Imaoka S, and Funae Y (1993) Characterization of specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats. Biochem Pharmacol 45:59-65.
20. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
21. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, and Bertilsson L (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6:441-447.
22. Saito K, Kim HS, Sakai N, Ishizuka M, Kazusaka A, and Fujita S (2004) Polymorphism in diazepam metabolism in Wistar rats. J Pharm Sci 93:1271-1278.
23. Schulz-Utermoehl T, Bennett AJ, Ellis SW, Tucker GT, Boobis AR, and Edwards RJ (1999) Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9:357-366.
24. Suzuki T, Narimatsu S, Fujita S, Masubuchi Y, Umeda S, Imaoka S, and Funae Y (1992) Purification and characterization of cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metab Dispos 20:367-373.
25. Towbin H, Staehelin T, and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
26. Vorhees CV, Morford LL, Inman SL, Reed TM, Schilling MA, Cappon GD, Moran MS, and Nebert DW (1999) Genetic differences in spatial leaming between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine. Pharmacogenetics 9:171-181.
27. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, and Wood AJ (1999) Allelic genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539-549.
28. Xie HG, Xu ZH, Luo X, Huang SL, Zeng FD, and Zhou HH (1996) Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis. Pharmacogenetics 6:235-238.
29. Yamamoto Y, Nakamura A, Tasaki T, Umeda S, Sugimoto C, Imaoka S, Funae Y, Masuda M, Kazuaka A, and Fujita S (1996) Impaired expression in DA rats of catalytically active P450BTL, immunochemically distinguishable from P4502D1: immunological evidence with specific anti-peptide antibodies. Biomed Res 17:331-337.
30. Yamamoto Y, Tasaki T, Nakamura A, lwata H, Kazusaka A, Gonzalez FJ, and Fujita S (1998) Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D and CYP2D2. Pharmacogenetics 8:73-82.
31. Zhou HH (2001) CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 313:203-208.